Compass Therapeutics Key Fundamental Indicators

Compass Therapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 125.3 M 161.5 M 94.2 M Slightly volatile Short and Long Term Debt Total 6.2 M 6 M 10.9 M Slightly volatile Other Current Liabilities 5.4 M 7.2 M 2.9 M Slightly volatile Total Current Liabilities 11.3 M 10.2 M 9.5 M Slightly volatile Property Plant And Equipment Net 4.9 M 8.1 M 5.1 M Very volatile Current Deferred Revenue 2 M 3.6 M 1.7 M Slightly volatile Accounts Payable 2.2 M 2.6 M 1.9 M Slightly volatile Cash 43.1 M 39.1 M 54.1 M Pretty Stable Non Current Assets Total 5.3 M 8.8 M 5.5 M Very volatile Non Currrent Assets Other 411.4 K 653.2 K 270.7 K Slightly volatile Long Term Debt 1.6 M 1.7 M 7.1 M Slightly volatile Cash And Short Term Investments 116.3 M 145.7 M 86 M Slightly volatile Common Stock Total Equity 11.1 K 11.7 K 1.5 M Slightly volatile Common Stock Shares Outstanding 85.7 M 157.7 M 48.8 M Slightly volatile Liabilities And Stockholders Equity 125.3 M 161.5 M 94.2 M Slightly volatile Non Current Liabilities Total 5.4 M 5.7 M 84.2 M Slightly volatile Other Current Assets 3.7 M 6.9 M 2.7 M Slightly volatile Total Liabilities 13 M 13.7 M 93.4 M Slightly volatile Property Plant And Equipment Gross 8.5 M 15.5 M 7.1 M Slightly volatile Short and Long Term Debt 6.1 M 8.6 M 5.3 M Slightly volatile Total Current Assets 120 M 152.7 M 88.7 M Slightly volatile Capital Stock 11.1 K 11.7 K 1.5 M Slightly volatile Net Working Capital 108.7 M 142.5 M 79.2 M Slightly volatile Short Term Debt 289 K 304.2 K 3 M Slightly volatile Common Stock 11.1 K 11.7 K 1.3 M Slightly volatile Property Plant Equipment 1.3 M 1.4 M 3.9 M Slightly volatile Long Term Debt Total 1.5 M 1.7 M 1.8 M Slightly volatile Capital Surpluse 373.9 M 523 M 278.8 M Slightly volatile Non Current Liabilities Other 855 900 2.2 M Slightly volatile Net Receivables 256 K 288 K 314.4 K Slightly volatile
Compass Therapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Interest Income 8.8 M 8.4 M 2.4 M Slightly volatile Depreciation And Amortization 1.6 M 1.6 M 1.9 M Slightly volatile Interest Expense 2.8 M 2.7 M 1.3 M Slightly volatile Selling General Administrative 13.5 M 17.4 M 12.1 M Slightly volatile Other Operating Expenses 52.1 M 66.1 M 44.5 M Slightly volatile Research Development 30.7 M 48.7 M 28.9 M Slightly volatile Cost Of Revenue 1.6 M 1.7 M 1.9 M Slightly volatile Total Operating Expenses 52.1 M 66.1 M 44.5 M Slightly volatile Reconciled Depreciation 1.6 M 1.6 M 1.9 M Slightly volatile Selling And Marketing Expenses 8.8 M 9.9 M 10.8 M Slightly volatile
Compass Therapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Stock Based Compensation 10.3 M 9.8 M 3.2 M Slightly volatile Begin Period Cash Flow 26.5 M 27.9 M 38.5 M Pretty Stable Depreciation 1.6 M 1.6 M 1.9 M Slightly volatile Capital Expenditures 37.6 K 39.6 K 1.2 M Slightly volatile Issuance Of Capital Stock 15.5 M 16.3 M 48.3 M Pretty Stable Total Cash From Financing Activities 14.8 M 15.6 M 51.2 M Slightly volatile End Period Cash Flow 43.2 M 39.1 M 54.3 M Pretty Stable Change To Netincome 5.7 M 6 M 5.5 M Slightly volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 187 210 230 Slightly volatile Stock Based Compensation To Revenue 8.06 9.06 9.8929 Slightly volatile Capex To Depreciation 0.0274 0.0289 0.6413 Slightly volatile EV To Sales 152 171 187 Slightly volatile Payables Turnover 0.89 1.0 1.0909 Slightly volatile Sales General And Administrative To Revenue 14.24 16.02 17.489 Slightly volatile Research And Ddevelopement To Revenue 39.85 44.83 48.9348 Slightly volatile Capex To Revenue 0.0414 0.0466 0.0509 Slightly volatile Cash Per Share 1.01 1.06 6.6535 Slightly volatile Days Payables Outstanding 263 296 323 Slightly volatile Income Quality 0.65 0.82 0.8343 Pretty Stable Net Debt To EBITDA 1.06 0.77 1.0651 Slightly volatile Current Ratio 8.59 13.46 8.9921 Slightly volatile Capex Per Share 4.0E-4 4.0E-4 0.2162 Slightly volatile Revenue Per Share 0.005 0.0056 0.0061 Slightly volatile Interest Debt Per Share 0.0529 0.0556 1.6892 Slightly volatile Debt To Assets 0.0516 0.0543 0.1723 Slightly volatile Days Of Payables Outstanding 263 296 323 Slightly volatile Ebt Per Ebit 1.06 1.0 0.9863 Pretty Stable Quick Ratio 8.59 13.46 8.9921 Slightly volatile Net Income Per E B T 1.1 1.15 1.0166 Slightly volatile Cash Ratio 5.94 5.64 6.1014 Pretty Stable Free Cash Flow Operating Cash Flow Ratio 1.12 1.15 1.0539 Very volatile Fixed Asset Turnover 0.096 0.11 0.118 Slightly volatile Debt Ratio 0.0516 0.0543 0.1723 Slightly volatile Price Sales Ratio 187 210 230 Slightly volatile Asset Turnover 0.0048 0.0054 0.0059 Slightly volatile
Compass Therapeutics Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 410.5 M 228.6 M 373 M Slightly volatile Enterprise Value 176.9 M 186.3 M 339.8 M Slightly volatile

Compass Fundamental Market Drivers

Compass Upcoming Events

Compass Shares Outstanding Driver Correlations

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details

Compass Therapeutics 'What if' Analysis

Hype Prediction Low Estimated High 2.62 6.41 10.20 Details

Intrinsic Valuation Low Real High 4.34 8.13 11.92 Details

9 Analysts Consensus Low Target High 12.25 13.46 14.94 Details

Earnings Estimates (0) Low Projected EPS High -0.15 -0.1 -0.05 Details

Compass Therapeutics February 13, 2026 Technical Indicators

Compass Therapeutics Backtested Returns

Competition

Predict Compass Therapeutics

Common Stock Shares Outstanding Over Time

Compass Common Stock Shares Outstanding

Compass Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Compass Therapeutics's current stock value. Our valuation model uses many indicators to compare Compass Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Compass Therapeutics competition to find correlations between indicators driving Compass Therapeutics's intrinsic value. More Info.Compass Therapeutics is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers . At this time, Compass Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Compass Therapeutics' earnings, one of the primary drivers of an investment's value.

Compass Shares Outstanding Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Compass Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Compass Therapeutics could also be used in its relative valuation, which is a method of valuing Compass Therapeutics by comparing valuation metrics of similar companies.

Compass Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Compass Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Compass Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Compass Fundamentals

About Compass Therapeutics Fundamental Analysis

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Compass Stock Analysis